HIGH DOSES OF STATINS BEFORE PERCUTANEOUS CORONARY INTERVENTION: WHETHER THERE ARE REASONS TO USE?
https://doi.org/10.20996/1819-6446-2017-13-4-532-540
Abstract
The results of prospective randomized clinical trials planned to assess the efficacy of using statins in high doses before percutaneous coronary interventions (PCI) are presented in the review. The effect of this approach on the severity of myocardial damage and clinical outcomes in planned PCI in patients with stable ischemic heart disease (IHD) and early PCI in acute coronary syndrome (ACS) without stable ST-segment elevation was found. The results of the trials planned to study the incidence of contrast-induced nephropathy as well as data from meta-analyzes of conducted clinical trials are demonstrated.
According to the accumulated facts, taking high doses of statins before PCI can contribute to reduce myocardial damage with a decrease in the risk of periprocedural myocardial infarction. This effect was demonstrated in the planned coronary stenting in patients with stable IHD and in PCI in the first days of treatment of ACS without the stable ST-segment elevation. It was found both in patients who had not previously taken statins and in patients permanently treated with statins. The additional expected benefit of using a high dose of statins prior to PCI is the prevention of contrast-induced nephropathy. However, due to the limited evidence base, there is no consensus on the advisability of such an approach in current clinical guidelines.
About the Authors
I. S. Yavelov
National Medical Research Centre for Preventive Medicine
Russian Federation
Russian Federation
MD, PhD, Leading Researcher, Department of Clinical Cardiology and Molecular Genetics,
Petroverigsky per. 10, Moscow, 101990
M. V. Zhatkina
National Medical Research Centre for Preventive Medicine
Russian Federation
Russian Federation
MD, Resident,
Petroverigsky per. 10, Moscow, 101990
O. M. Drapkina
National Medical Research Centre for Preventive Medicine
Russian Federation
Russian Federation
MD, PhD, Professor, Corresponding Member of Russian Academy of Science, Acting Director,
Petroverigsky per. 10, Moscow, 101990
A. Yu. Gorshkov
National Medical Research Centre for Preventive Medicine
Russian Federation
Russian Federation
MD, PhD, Head of Department of Emergency Cardiology with an Intensive Care Unit,
Petroverigsky per. 10, Moscow, 101990
N. O. Myasnikova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Sixth-Year Student,
Ostrovitianova ul. 1, Moscow, 117997
References
1. Pasceri V., Patti G., Nusca A., et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA study. Circulation. 2004;110:674-8.
2. Briguori С., Visconti G., Focaccio A., et al. Novel Approaches for Preventing or Limiting Events (Naples) II Trial: Impact of a Single High Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction. JACC. 2009;54:2157-63.
3. Patti G., Pasceri V., Colonna G., et al. Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention. Results oftheARMYDA-ACS Randomized Trial. JACC. 2007;49:1272-8.
4. Sciascio G., Patti G., Pasceri V., et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE Randomized Trial. JACC. 2009;54:558-65.
5. Sardella G., Lucisano L., Mancone M., et al. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial. Int J Cardiol. 2013;168:3715-20.
6. Winchester D.E., Wen X., Xie L., Bavry A.A. Evidence of Pre-Procedural Statin Therapy. A Meta-Analysis of Randomized Trials. JАСС. 2010;56:1099-109.
7. Lyu T., Zhao Y., Zhan T., et al. Effect of Statin Pretreatment on Myocardial Perfusion in Patients Undergoing Primary Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. Clin Cardiol. 2013;69:E17-E24.
8. Jang Y., Zhu J., Ge J., et al. Preloading with atorvastatin before percutaneous coronary intervention in statin-naХve Asian patients with non-ST elevation acute coronary syndromes: A randomized study. J Cardiol. 2014;63:335-43.
9. Lyu T., Zhao Y., Zhang T., et al. Effect of Statin Pretreatment on Myocardial Perfusion in Patients Undergoing Primary Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. Clin Cardiol. 2013;36:E17-E24.
10. Patti G., Ricottini E., Nusca A., et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN trial). Am J Cardiol. 2011;108:1-7.
11. Leoncini M., Toso A., Maioli M., et al. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). JACC. 2014;63:71-9.
12. Singh N, Lee J.,Huang J., et al. Benefit of statin pretreatmentin prevention of contrast-induced nephropathy in different adult patient population: systematic review and meta-analysis. Open Heart. 2014;1(1):e000127.
13. Roffi M., Patrono C., ColletJ.P., et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315.
14. Steg P.G., James S.K., Atar D., et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33:2569-619.
15. O'Gara P.T., Kushner F.G., Ascheim D.D., et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JACC. 2013;61:485-510.
16. Amsterdam E.A., Wenger N.K., Brindis R.G., et al. 2014 AHA/ACC Guidelines for the Management of Patients With Non-ST-Elevation Acute Coronary Syndrome: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e344-e426.
17. Windecker S., Kolh P., Alfonso F., et al. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-619.
18. Levine G.N., Bates E.R., Blankenship J.C., et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Am Coll Cardiol. 2011;58(24):e44-122.
19. Catapano A.L., Graham I., De Backer G., et al. 2016 ESC/EAS Guidelines for the Managementof Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;253:281-344.
20. Aronov D.M., Arabidze G.G., Akhmedzhanov N.M., et al. Diagnosis and correction of lipid metabolism disorders for the purpose of prevention and treatment of atherosclerosis. Russian recommendations, V revision. Rossiyskiy Kardiologicheskiy Zhurnal. 2012;96(4):2-32. (In Russ.) [Аронов Д.М., Арабидзе Г.Г., Ахмеджанов Н.М., и др.Диагностике и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, V пересмотр. Российский Кардиологический Журнал. 2012; 96(4):2-32].
Review
For citations:
Yavelov I.S., Zhatkina M.V., Drapkina O.M., Gorshkov A.Yu., Myasnikova N.O. HIGH DOSES OF STATINS BEFORE PERCUTANEOUS CORONARY INTERVENTION: WHETHER THERE ARE REASONS TO USE? Rational Pharmacotherapy in Cardiology. 2017;13(4):532-540. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-4-532-540
Views:
685
.jpg)
Email this article 